by Typhoid fever vaccines help to protect against infection caused by Salmonella Typhi bacteria. It causes enteric (intestinal) fever and affects over 20 million people globally each year, especially in areas with limited access to clean water and sanitation. The vaccines are available as live oral vaccines (Vivotif and Ty21a) and injectable vaccines (ViPS and Typherix). The oral vaccines use attenuated (weakened) Salmonella Typhi bacteria to produce immunity. The injectable vaccines are usually recommended for travelers to typhoid-endemic countries.
The global Typhoid Fever Vaccines Market is estimated to be valued at Us$ 394.27 Mn in 2023 and is expected to exhibit a CAGR Of 7.5% over the forecast period of 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics
High burden of typhoid fever in developing nations is expected to drive the growth of typhoid fever vaccines market over the forecast period. According to World Health Organization (WHO), every year over 21 million new cases of typhoid fever are estimated to occur worldwide, with majority of these cases occurring in developing countries of Asia, Africa, and Latin America with limited access to clean water and sanitation facilities. Typhoid fever remains a major public health problem in many developing countries where sanitation remains poor. Therefore, developing nations with high burden of typhoid fever will create significant opportunity for adoption of typhoid fever vaccines, hence driving market growth.
The other driver for typhoid fever vaccines market is availability of funding for typhoid control programmes. Major foundations and organizations are offering funding to several Asian and African countries for typhoid control, including vaccination programs. For example, the Typhoid Vaccine Acceleration Consortium (TYVAC), funded by a gift from the Bill & Melinda Gates Foundation, is working with countries to introduce new typhoid conjugate vaccines into their national immunization programs. Such initiatives will help the eligible countries to adopt vaccination programmes and support market growth over the forecast period.
Segment Analysis
The typhoid fever vaccines market is dominated by the oral live-attenuated typhoid vaccines segment, which holds around 75% of the market share. This segment is leading because oral live-attenuated typhoid vaccines, such as Ty21a and Vi capsular polysaccharide vaccine offer better protection for longer duration against typhoid compared to injectable polysaccharide vaccines. They are also more convenient as they can be administered without medical supervision.
PEST Analysis
Political: The presence of strict regulation for approval of vaccines across regions acts as a driver for the typhoid fever vaccines market. Various governments are also raising awareness about typhoid prevention which is increasing the demand for vaccines.
Economic: Developing countries in Asia Pacific and Africa are witnessing higher economic growth and this is increasing healthcare spending. Rise in per capita incomes also increases affordability of costlier typhoid vaccines in these regions.
Social: In developing nations, poor sanitation and unsafe water supplies are leading causes of typhoid infection. Non-profit organizations are working towards education and promotion of hygiene practices to control the disease.
Technological: Advancements are being made to develop more effective typhoid vaccines that can provide lifelong immunity with single dose. Researchers are also working on thermostable oral vaccines that do not require cold chain transportation.
Key Takeaways
The Global Typhoid Fever Vaccines Market Demand is expected to witness high growth at a CAGR of 7.5% during the forecast period of 2023 to 2030.
Regional analysis shows that Asia Pacific currently holds the largest market share of around 40% owing to high disease prevalence in countries like India. The region is also expected to grow at the fastest rate due to growing vaccination programs in countries like China, India and Vietnam.
Key players operating in the typhoid fever vaccines market are BASF SE, Croda Health Care, JRS Pharma, Lipoid GmbH, Azelis, U.K. Vet Chem, Gattefoss, Synergy API, Anzchem, Vantage. Key players are focused on expanding their production capacities and geographical presence through collaborations with regional distribution partners to cater to the rising demand.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
